KR20220029681A - 특발성 폐 섬유증의 치료 방법 - Google Patents

특발성 폐 섬유증의 치료 방법 Download PDF

Info

Publication number
KR20220029681A
KR20220029681A KR1020227002368A KR20227002368A KR20220029681A KR 20220029681 A KR20220029681 A KR 20220029681A KR 1020227002368 A KR1020227002368 A KR 1020227002368A KR 20227002368 A KR20227002368 A KR 20227002368A KR 20220029681 A KR20220029681 A KR 20220029681A
Authority
KR
South Korea
Prior art keywords
days
compound
group
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227002368A
Other languages
English (en)
Korean (ko)
Inventor
얀핑 자오
홍준 왕
유안유안 지앙
웨이팅 종
징 자오
징 리
웨이나 리우
리잉 저우
야난 리우
Original Assignee
베이징 타이드 파마슈티컬 코퍼레이션 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 filed Critical 베이징 타이드 파마슈티컬 코퍼레이션 리미티드
Publication of KR20220029681A publication Critical patent/KR20220029681A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227002368A 2019-06-25 2020-06-24 특발성 폐 섬유증의 치료 방법 Pending KR20220029681A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019092675 2019-06-25
CNPCT/CN2019/092675 2019-06-25
PCT/CN2020/097881 WO2020259528A1 (zh) 2019-06-25 2020-06-24 治疗特发性肺纤维化的方法

Publications (1)

Publication Number Publication Date
KR20220029681A true KR20220029681A (ko) 2022-03-08

Family

ID=74061495

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002368A Pending KR20220029681A (ko) 2019-06-25 2020-06-24 특발성 폐 섬유증의 치료 방법

Country Status (11)

Country Link
US (1) US12582653B2 (https=)
EP (1) EP3992183A4 (https=)
JP (1) JP7615061B2 (https=)
KR (1) KR20220029681A (https=)
CN (2) CN114026072A (https=)
AU (1) AU2020305979B2 (https=)
BR (1) BR112021026214A2 (https=)
CA (1) CA3144113A1 (https=)
IL (1) IL289192A (https=)
TW (1) TWI804743B (https=)
WO (1) WO2020259528A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023539276A (ja) * 2020-08-31 2023-09-13 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ関連タンパク質キナーゼ阻害剤の塩、その固体形態、その調製方法およびその使用
CA3209240A1 (en) * 2021-02-22 2022-08-25 Samuel D. Waksal Rock2 inhibitor for the treatment of viral infection
NO346587B1 (en) * 2021-06-02 2022-10-17 Axichem Ab Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
TW202327608A (zh) * 2021-09-17 2023-07-16 北京泰德製藥股份有限公司 治療病毒感染的方法
IL311447A (en) * 2021-09-18 2024-05-01 Beijing Tide Pharmaceutical Co Ltd A solid form of a Rho-linked protein kinase inhibitor or a solvate thereof, a method of preparation and use thereof
KR20240095429A (ko) * 2021-11-16 2024-06-25 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Rock2 억제제의 나노결정 제제 및 이의 제조방법
WO2023134688A1 (zh) * 2022-01-13 2023-07-20 武汉朗来科技发展有限公司 一种rock抑制剂的盐及盐的晶型、组合物和药物用途
EP4591863A1 (en) * 2022-10-13 2025-07-30 Beijing Tide Pharmaceutical Co., Ltd. Method for treating pneumoconiosis
WO2025017499A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
IL325831A (en) 2023-07-17 2026-03-01 Graviton Bioscience Bv ROCK2 inhibitor formulations for central nervous system disorders
WO2025069008A1 (en) 2023-09-28 2025-04-03 Graviton Bioscience Bv Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138335A1 (en) * 2015-02-27 2016-09-01 Lycera Corporation Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
AR110401A1 (es) 2016-12-21 2019-03-27 Chiesi Farm Spa Derivados dihidropirimidina bicíclica-carboxamida como inhibidores de rho-quinasa
CN110582489B (zh) * 2017-06-30 2023-10-27 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019000682A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
EP3992183A1 (en) 2022-05-04
US20220233538A1 (en) 2022-07-28
EP3992183A4 (en) 2023-06-21
TW202114679A (zh) 2021-04-16
US12582653B2 (en) 2026-03-24
AU2020305979A1 (en) 2022-02-17
IL289192A (en) 2022-02-01
JP2022539329A (ja) 2022-09-08
JP7615061B2 (ja) 2025-01-16
CN114026072A (zh) 2022-02-08
AU2020305979B2 (en) 2026-04-23
WO2020259528A1 (zh) 2020-12-30
CA3144113A1 (en) 2020-12-30
CN119868365A (zh) 2025-04-25
TWI804743B (zh) 2023-06-11
BR112021026214A2 (pt) 2022-02-15

Similar Documents

Publication Publication Date Title
US12582653B2 (en) Method for treating idiopathic pulmonary fibrosis
KR101591701B1 (ko) 저산소증 유발 인자-1 알파의 안정화 증가 방법
KR102935436B1 (ko) 디아미노피리미딘 화합물을 사용한 기침 치료 방법
JP7803924B2 (ja) 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法
WO2024050434A1 (en) ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
EP4591863A1 (en) Method for treating pneumoconiosis
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
HK40121343A (zh) 治疗特发性肺纤维化的方法
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
HK40086216A (en) Method for treating graft versus host disease caused by hematopoietic stem cell transplantation
JP2025529076A (ja) ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000